S314
Clinical - Breast
ESTRO 2026
and an acceptable safety profile in carefully selected low-risk breast cancer patients. These results support the use of IORT as a standalone treatment in de- escalation strategies. Careful preoperative selection remains key to minimizing the need for additional treatment and maximizing therapeutic benefit. Keywords: IORT, Intrabeam, therapeutic de-escalation Mini-Oral 3959 Acute radiation side effects of proton versus photon therapy following surgery for early breast cancer or DCIS: a sub-study of the DBCG PROTON Trial Kristine W Høgsbjerg 1,2 , Stine E Petersen 3 , Else Maae 4 , Louise W Matthiessen 5 , Mette Møller 6 , Sami A-J Al- Rawi 7 , Maja V Maraldo 8 , Mette H Nielsen 9 , Birgitte V Offersen 1,2 1 Department of Experimental Clinical Oncology, Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 2 Department of Clinical Medicin, Aarhus University, Aarhus, Denmark. 3 Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark. 4 Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark. 5 Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark. 6 Department of Oncology, Aalborg University Hospital, Aalborg, Denmark. 7 Department of Oncology, Zealand University Hospital, Næstved, Denmark. 8 Dept. of Clinical Oncology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. 9 Department of Oncology, Odense University Hospital, Odense, Denmark
Digital Poster 3961
Hypofractionated 3D-CRT with simultaneous integrated boost for locoregional breast cancer: Prospective assessment of acute skin adverse events Raouia Ben Amor 1,2 , Siwar Abdessaied 1,2 , Syrine Lahiouel 1,2 , Zeineb Naimi 1,2 , Ghada Bouguerra 1 , Rihab Haddad 1 , Awatef Hamdoun 1 , Lotfi Kochbati 1,2 1 Radiation Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia. 2 Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia Purpose/Objective: In this study, we aimed to assess acute skin adverse events (ASAE) in breast cancer patients treated with hypofractionated 3D-CRT with simultaneous integrated boost (SIB), with or without regional lymph node irradiation (RLNI) after breast-conserving surgery(BCS), and analyze correlations with dosimetric parameters. Material/Methods: We prospectively evaluated breast cancer patients treated with HFRT using a 3D-SIB after BCS between February 2024 to June 2025. The prescribed dose was 40 Gy to the whole breast (WB)and 48 Gy in 15 fractions to the tumor bed in SIB, with or without RLNI. The following dosimetric parameters for both
Made with FlippingBook - Share PDF online